NEW YORK (GenomeWeb) – Foundation Medicine said today that it is partnering with Cancer Outcomes Tracking and Analysis (COTA) to analyze genomic information, clinical outcome, and cost data from patients whose tumors have been tested with FoundationOne.
The goal is to provide healthcare providers and payors with evidence that informs value-based reimbursement decisions and cancer treatment.
The firms will first focus on patients who are newly diagnosed with Stave IV non-small cell lung cancer and are enrolled in a health plan that has agreed to participate in the collaboration.
Subsequent phases of the collaboration are still under discussion, but may include any or all of the remaining cancer indications for FoundationOne and FoundationOne Heme, sequencing-based genomic profiling tests for solid tumors and hematological cancers, respectively.
"Eliminating inefficiencies and improving patient care requires actionable insights supported by complete, integrated data," COTA CEO Eric Schultz said in a statement, adding that the collaboration will "provide insights that enable both physicians and payors to move toward value-based treatment and reimbursement practices."
"The capture of clinical outcomes resulting from treatment selection informed by our comprehensive genomic profiles is essential to demonstrating the clinical and economic value of FoundationOne and to expanding utilization and access for these tests," Foundation Medicine CEO Michael Pellini said in a statement.
The deal is Foundation Medicine's second this week. Yesterday, the firm announced it would partner with EmergingMed to help healthcare providers identify appropriate clinical trials for their patients that had been tested with FoundationOne and FoundationOne Heme.